High-Risk DLBCL: GOLCA Boosts Remission Rates | Marc Hoffmann, MD

High-Risk DLBCL: GOLCA Boosts Remission Rates | Marc Hoffmann, MD
Chemo-Free Option for Frail Lymphoma Patients | Umberto Vitolo, MD
What Happens When You Add Mosunetuzumab + Polatuzumab to CAR‑T (axi‑cel)? | Jay Spiegel, MD
SMART STOP Trial: Targeted Drugs Before Chemo in B-Cell Lymphoma? | Jason Westin, MD
Can Epcoritamab Improve Outcomes in R-mini-CHOP Patients? | Chan Cheah, MD, PhD
Promising Therapy for Hard-to-treat DLBCL: Epcoritamab + GemOx #DLBCL | Joshua Brody, MD
What should patients expect during and after treatment with CAR T-cell therapy?
Which drugs are FDA approved for bispecific therapy and how do they work?
What You Need to Know About Blood Transfusions in Cancer Treatment
